Update on review of COVID-19 Vaccine AstraZeneca and thromboembolic events with concurrent low platelet counts

In view of the available data, the CHM says COVID-19 Vaccine AstraZeneca is contraindicated in patients with a history of major venous and arterial thrombosis with thrombocytopenia. But the overall the vaccine benefits against COVID-19 continue to outweigh any risks in the vast majority of people.
Update on review of COVID-19 Vaccine AstraZeneca and thromboembolic events with concurrent low platelet counts

Join OnMedica and benefit from:

  • Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
  • High-quality, evidence-based content developed by expert editors and clinicians
  • Articles, quizzes, videos, visual summaries and more
  • Regulatory alerts and round-up of medical journals
  • New content added daily, so you know you’re always up to date
Register

Existing members Sign in

Sorry, we need to confirm your details before you can access this content.

If you have just signed up to OnMedica, you are seeing this message because we couldn’t automatically verify that you are a practising doctor in the UK. Please check your email inbox as we may need a few more details to validate your OnMedica membership. If you haven’t received an email from us or you need assistance, please contact customer.services@onmedica.com.